Sarepta Therapeutics, Inc. (SRPT)

NASDAQ: SRPT · IEX Real-Time Price · USD
109.00
-0.26 (-0.24%)
At close: Aug 12, 2022 4:00 PM
111.00
+2.00 (1.83%)
After-hours: Aug 12, 2022 6:49 PM EDT
-0.24%
Market Cap 9.54B
Revenue (ttm) 835.18M
Net Income (ttm) -506.63M
Shares Out 87.57M
EPS (ttm) -4.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,028,665
Open 109.30
Previous Close 109.26
Day's Range 108.61 - 110.96
52-Week Range 61.28 - 113.60
Beta 1.26
Analysts Buy
Price Target 120.64 (+10.7%)
Earnings Date Aug 2, 2022

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skip... [Read more...]

Industry Biotechnology
IPO Date Jun 3, 1997
CEO Douglas Ingram
Employees 840
Stock Exchange NASDAQ
Ticker Symbol SRPT
Full Company Profile

Financial Performance

In 2021, SRPT's revenue was $701.89 million, an increase of 29.96% compared to the previous year's $540.10 million. Losses were -$418.78 million, -24.43% less than in 2020.

Financial Statements

Analyst Forecast

According to 27 analysts, the average rating for SRPT stock is "Buy." The 12-month stock price forecast is 120.64, which is an increase of 10.68% from the latest price.

Price Target
$120.64
(10.68% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Sarepta Therapeutics Announces Progress on the MyoAAV Program and Exclusive Licensing Agreement with The Broad Instit...

Following internal corroboration of published results on the MyoAAV platform, Sarepta secures exclusive license for Duchenne muscular dystrophy, plus four additional neuromuscular and cardiac indications

Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust

Strong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.

Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -147.66% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments

-  Total revenues, which consist of net product revenues and collaboration revenues, for the second quarter 2022 totaled $233.5 million

Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.2% Jump Turn into More Strength?

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 29, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 29, 2022 that were...

Why Sarepta Therapeutics Stock Is Perking Up Today

The biotech's gene therapy for Duchenne's muscular dystrophy could hit the market sooner than expected.

Sarepta (SRPT) Stock Gains on FDA News

Source: Panuwach/Shutterstock Sarepta Therapeutics (NASDAQ: SRPT ) stock is rising higher on Friday thanks to an update concerning its Duchenne muscular dystrophy treatment. According to the company, it...

Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Th...

CAMBRIDGE, Mass., July 29, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced its intent to submit a Biologics...

Sarepta Therapeutics to Announce Second Quarter 2022 Financial Results and Recent Corporate Developments on August 2,...

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2022 financial result...

Here's Why Sarepta Therapeutics (SRPT) is a Great Momentum Stock to Buy

Does Sarepta Therapeutics (SRPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial

Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new functional data across multiple studies from the SRP-9001 (delandistrogene moxeparvovec) program for Duchenne muscular dystrophy.  SRP-9001 is an inves...

Sarepta Therapeutics' Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant ...

CAMBRIDGE, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared new functional data across multiple...

Sarepta Has New Gene Therapy Data Coming. What It Could Mean for the Stock.

Sarepta will update investors Thursday on the data it hopes will persuade U.S. regulators to accelerate approval of its gene therapy treatment for muscular dystrophy.

Sarepta Therapeutics to Share New Clinical Data and Integrated Analysis for SRP-9001, its Investigational Gene Therap...

CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wednesday, July 6, 2022 ...

Sarepta (SRPT) Down on Clinical Hold on DMD Candidate SRP-5051

The FDA places Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, on clinical hold, following a report of hypomagnesemia in the ongoing phase II MOMENTUM study.

Sarepta stock plunges after FDA puts study on hold

Sarepta Therapeutics Inc. SRPT, +5.14% shares plummeted as much as 20% in after-hours trading Thursday, after the company reported that a study had been put on hold by the Food and Drug Administration. ...

Sarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy

- Sarepta to host conference call at 4:15 p.m. Eastern time

Why Is Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

Sarepta Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will part...

Sarepta (SRPT) Q1 Earnings Beat, DMD Drugs' Sales Robust

Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the first quarter. Stock up in after-market trading.

Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 11.11% and 3.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will parti...

Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarepta Therapeutics to Announce First Quarter 2022 Financial Results and Recent Corporate Developments on May 4, 2022

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2022 financial result...